![Locally advanced gastrointestinal cancers: moving forward in the neoadjuvant setting](/var/esmo/storage/images/esmo-daily-reporter/spotlight/locally-advanced-gastrointestinal-cancers-moving-forward-in-the-neoadjuvant-setting/19183082-1-eng-GB/locally-advanced-gastrointestinal-cancers-moving-forward-in-the-neoadjuvant-setting_i770.jpg)
Locally advanced gastrointestinal cancers: moving forward in the neoadjuvant setting
Recent results from research have changed the treatment paradigm for some digestive tumours, but further evidence is needed to finetune the neoadjuvant approach
![Breast cancer research: lessons learnt from the past will shape the future](/var/esmo/storage/images/esmo-daily-reporter/esmo-breast-cancer-2024/esmo-breast-cancer-2024/breast-cancer-research-lessons-learnt-from-the-past-will-shape-the-future/19126498-3-eng-GB/breast-cancer-research-lessons-learnt-from-the-past-will-shape-the-future_i770.jpg)
Breast cancer research: lessons learnt from the past will shape the future
In her key lecture, the 2024 ESMO Breast Cancer Awardee Prof. Hope S. Rugo reflects on the current challenges in the field
![Extending the continuum of care for metastatic colorectal cancer](/var/esmo/storage/images/esmo-daily-reporter/spotlight/extending-the-continuum-of-care-for-metastatic-colorectal-cancer/19120352-1-eng-GB/extending-the-continuum-of-care-for-metastatic-colorectal-cancer_i770.jpg)
Extending the continuum of care for metastatic colorectal cancer
While novel agents continue to enrich the therapeutic armamentarium in this setting, patients ask for a longer survival, but also for a better quality of life
![Treating colorectal cancer in the biomarker era – what's next?](/var/esmo/storage/images/esmo-daily-reporter/spotlight/treating-colorectal-cancer-in-the-biomarker-era-what-s-next/18185084-3-eng-GB/treating-colorectal-cancer-in-the-biomarker-era-what-s-next_i770.jpg)
Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
![Research in upper gastrointestinal cancers makes a leap forward](/var/esmo/storage/images/esmo-daily-reporter/spotlight/research-in-upper-gastrointestinal-cancers-makes-a-leap-forward/18734748-3-eng-GB/research-in-upper-gastrointestinal-cancers-makes-a-leap-forward_i770.jpg)
Research in upper gastrointestinal cancers makes a leap forward
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
![How ‘precise’ has lung cancer treatment become?](/var/esmo/storage/images/esmo-daily-reporter/european-lung-cancer-congress-2024/highlights-from-elcc-2024/how-precise-has-lung-cancer-treatment-become/18933293-3-eng-GB/how-precise-has-lung-cancer-treatment-become_i770.jpg)
How ‘precise’ has lung cancer treatment become?
Precision oncology is evolving from advanced to early-stage NSCLC, highlights Prof. Enriqueta Felip in her Heine H. Hansen Award lecture at ELCC 2024
![Wider implementation of precision oncology is still challenging](/var/esmo/storage/images/esmo-daily-reporter/esmo-targeted-anticancer-therapies-congress-2024/news/wider-implementation-of-precision-oncology-is-still-challenging/18865254-3-eng-GB/wider-implementation-of-precision-oncology-is-still-challenging_i770.jpg)
Wider implementation of precision oncology is still challenging
The 2024 TAT Honorary Awardee Prof. Funda Meric-Bernstam discusses progress made and how to overcome current obstacles in the field
![Challenges in cell-based immunotherapies create opportunities for progress](/var/esmo/storage/images/esmo-daily-reporter/esmo-immuno-oncology-congress-2023/highlights/challenges-in-cell-based-immunotherapies-create-opportunities-for-progress/18666437-1-eng-GB/challenges-in-cell-based-immunotherapies-create-opportunities-for-progress_i770.png)
Challenges in cell-based immunotherapies create opportunities for progress
According to the 2023 ESMO Immuno-Oncology Awardee, Steven A. Rosenberg, the keys to progress are identifying the optimal characteristics of antitumour effector lymphocytes, cancer antigen identification and strategies for overcoming resistance mechanisms to enhance immune-cell function
![The future of real-world research is now](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2023/top-news/the-future-of-real-world-research-is-now/18277565-1-eng-GB/the-future-of-real-world-research-is-now_i770.jpg)
The future of real-world research is now
ESMO is at the forefront of digital oncology, with some initiatives that support oncologists navigating the emerging opportunities in the field of real-world data research
![Being good as a role model does not depend on gender](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2023/2023-esmo-society-awards/being-good-as-a-role-model-does-not-depend-on-gender/18271533-7-eng-GB/being-good-as-a-role-model-does-not-depend-on-gender_i770.jpg)
Being good as a role model does not depend on gender
ESMO Women for Oncology Awardee Prof. Georgina Long talks of addressing gender bias in oncology